Site-specific herbicide applications with remotely piloted aerial application systems (RPAASs) offer the potential for reducing herbicide inputs in turfgrass systems. However, information on spray nozzle selection and application volume for this approach is lacking. The objective of this study was to evaluate the effects of nozzle type and spray volume on the efficacy of site-specific herbicide application to turf using an RPAAS, focusing on large crabgrass control with quinclorac. The research was conducted in 2022 at two sites in College Station, TX. The treatments were combinations of three nozzle types (XR 80-015 [conventional, extended range], DG 80-015 [drift guard], and AI 80-015 [air induction] flat-fan nozzles) and two spray volumes (10 and 15 L ha−1), applied with a single-nozzle RPAAS. A spray volume of 102 L ha−1 applied with a CO2-pressurized four-nozzle boom backpack sprayer served as a check for comparison. Two additional treatments were also included: a pure formulated herbicide application (without dilution in water) using an RPAAS equipped with an XR 80-005 flat-fan nozzle at 4.6 L ha−1, and an untreated control. The backpack sprayer application resulted in the highest spray solution deposits on large crabgrass plants (12 times more on average), compared to the RPAAS applications. Nevertheless, applications using the RPAAS with the DG and AI nozzles at 10 or 15 L ha−1 provided similar levels of weed control as that of the backpack sprayer at 102 L ha−1, indicating that RPAAS can be effectively used for site-specific herbicide applications to turf. This study also suggests that large crabgrass can be controlled using RPAAS with a range of spray nozzle types at low application volumes to turfgrass. Further research is needed to assess the efficacy of RPAAS-based herbicide applications across a range of herbicides, weed species, and environmental conditions.

Foliar-applied postemergence applications of glufosinate are often applied to glufosinate-resistant crops to provide nonselective weed control without significant crop injury. Rainfall, air temperature, solar radiation, and relative humidity near the time of application have been reported to affect glufosinate efficacy. However, previous research may have not captured the full range of weather variability to which glufosinate may be exposed before or following application. Additionally, climate models suggest more extreme weather will become the norm, further expanding the weather range to which glufosinate can be exposed. The objective of this research was to quantify the probability of successful weed control (efficacy ≥85%) with glufosinate applied to some key weed species across a broad range of weather conditions. A database of >10,000 North American herbicide evaluation trials was used in this study. The database was filtered to include treatments with a single postemergence application of glufosinate applied to waterhemp [Amaranthus tuberculatus (Moq.) Sauer], morningglory species (Ipomoea spp.), and/or giant foxtail (Setaria faberi Herrm.) <15 cm in height. These species were chosen because they are well represented in the database and listed as common and troublesome weed species in both corn (Zea mays L.) and soybean [Glycine max (L.) Merr.] (Van Wychen 2020, 2022). Individual random forest models were created. Low rainfall (≤20 mm) over the 5 d before glufosinate application was detrimental to the probability of successful control of A. tuberculatus and S. faberi. Lower relative humidity (≤70%) and solar radiation (≤23 MJ m−1 d−1) on the day of application reduced the probability of successful weed control in most cases. Additionally, the probability of successful control decreased for all species when average air temperature over the first 5 d after application was ≤25 C. As climate continues to change and become more variable, the risk of unacceptable control of several common species with glufosinate is likely to increase.

Foliar-applied postemergence herbicides are a critical component of corn (Zea mays L.) and soybean [Glycine max (L.) Merr.] weed management programs in North America. Rainfall and air temperature around the time of application may affect the efficacy of herbicides applied postemergence in corn or soybean production fields. However, previous research utilized a limited number of site-years and may not capture the range of rainfall and air temperatures that these herbicides are exposed to throughout North America. The objective of this research was to model the probability of achieving successful weed control (≥85%) with commonly applied postemergence herbicides across a broad range of environments. A large database of more than 10,000 individual herbicide evaluation field trials conducted throughout North America was used in this study. The database was filtered to include only trials with a single postemergence application of fomesafen, glyphosate, mesotrione, or fomesafen + glyphosate. Waterhemp [Amaranthus tuberculatus (Moq.) Sauer], morningglory species (Ipomoea spp.), and giant foxtail (Setaria faberi Herrm.) were the weeds of focus. Separate random forest models were created for each weed species by herbicide combination. The probability of successful weed control deteriorated when the average air temperature within the first 10 d after application was <19 or >25 C for most of the herbicide by weed species models. Additionally, drier conditions before postemergence herbicide application reduced the probability of successful control for several of the herbicide by weed species models. As air temperatures increase and rainfall becomes more variable, weed control with many of the commonly used postemergence herbicides is likely to become less reliable.

Observations of glacier melt and runoff are of fundamental interest in the study of glaciers and their interactions with their environment. Considerable recent interest has developed around distributed acoustic sensing (DAS), a sensing technique which utilizes Rayleigh backscatter in fiber optic cables to measure the seismo-acoustic wavefield in high spatial and temporal resolution. Here, we present data from a month-long, 9 km DAS deployment extending through the ablation and accumulation zones on Rhonegletscher, Switzerland, during the 2020 melt season. While testing several types of machine learning (ML) models, we establish a regression problem, using the DAS data as the dependent variable, to infer the glacier discharge observed at a proglacial stream gauge. We also compare two predictive models that only depend on meteorological station data. We find that the seismo-acoustic wavefield recorded by DAS can be utilized to infer proglacial discharge. Models using DAS data outperform the two models trained on meteorological data with mean absolute errors of 0.64, 2.25 and 2.72 m3 s−1, respectively. This study demonstrates the ability of in situ glacier DAS to be used for quantifying proglacial discharge and points the way to a new approach to measuring glacier runoff.

OBJECTIVES/GOALS: Venous thromboembolism (VTE) is a major cause of morbidity and mortality. Due to its relatively low incidence, prospective studies are limited. This makes administrative claims a promising data source to study VTE. We sought to examine the reproducibility of results using different VTE definitions from the published literature. METHODS/STUDY POPULATION: We conducted a retrospective analysis of a random 10% sample of the 2010-2022 IQVIA LifeLink PharMetrics Plus™ database, an administrative claims database representative of the commercially insured population of the United States. We selected cancer patients undergoing major gastrointestinal surgery, who have a higher risk for postoperative VTE (deep venous thrombosis [DVT] and/or pulmonary embolism [PE]). VTE was defined using ICD-9-CM and ICD-10-CM codes using definitions from 4 individual published studies. We compared the 4 definitions with respect to the incidence of VTE and factors associated with post-discharge VTE using standard univariate and multivariable logistic regression models. The same logistic regression models were used for each of the 4 definitions. RESULTS/ANTICIPATED RESULTS: There were substantial differences in VTE coding among the 4 definitions (range 107 to 225 ICD-9/10 codes for DVT and 12 to 24 codes for PE). The eligible population comprised 2,360 patients (49% female) with a median age of 49 years (interquartile range 47-52 years). During the index surgery hospitalization, a total of 58, 62, 63, and 83 patients developed VTE using the 4 definitions. In the 2,126 patients eligible for VTE prophylaxis, a total of 108, 68, 73, and 107 patients developed post-discharge VTE (range for DVT 35 to 81, range for PE 39 to 76). On multivariable analysis, factors independently associated with VTE included age using 1 of 4 definitions, esophageal surgery type using 3 of 4 definitions, and liver surgery type and Elixhauser score using all 4 definitions. DISCUSSION/SIGNIFICANCE: The incidence of VTE is directly affected by differences in ICD-9/10 codes used. Definitions for important clinical outcomes should be standardized when using administrative claims data in order to improve reproducibility of findings.

Conservation monitoring is paramount for the gathering of information on species and populations in need of conservation actions. However, monitoring of the mountain bongo Tragelaphus eurycerus isaaci, a Critically Endangered antelope endemic to Kenya, has hitherto been limited to surveillance (i.e. focused on persistence of the species in particular areas), thus limiting the information that could be retrieved on the status and trends of these populations. Using a newly developed identification system, we implemented robust design mark–recapture using existing camera-trap records of four wild subpopulations of the bongo. We provide data on sex and age structure and the first estimates of population size in the wild. Males and calves seem to be suffering higher mortality than females, and only two of the four monitored populations include adults of both sexes and calves. The combined size of these two breeding populations is estimated to be 29–50. Our findings confirm the critical situation of the mountain bongo in the wild and highlight the need for conservation actions to reinforce the wild populations for the long-term conservation of this antelope.

California is the top producer of almonds [Prunus dulcis (Mill.) D.A. Webb] worldwide, generating more than $6 billion in revenue in 2020; the European Union (EU) is the primary importer of California almonds. Weed control in almond orchards is an important part of the preharvest process, because weeds can interfere with harvest equipment and host diseases. Glyphosate and glufosinate are broad-spectrum herbicides commonly used for preharvest weed control. Global differences in maximum residue limits (MRLs) and regulated compounds can pose a challenge for growers who rely on broad-spectrum herbicides such as glyphosate and glufosinate for preharvest weed control. The EU MRL for glyphosate and total glufosinate is currently 0.1 mg kg−1. The U.S. MRL for total glyphosate is 1 mg kg−1, and total glufosinate is 0.5 mg kg−1. An 8-wk field experiment, from spray to harvest, was conducted in an 8-ha commercial orchard to evaluate the potential contribution of the preharvest herbicide treatment to low levels of herbicide residue in almonds. Then, the same batch of almonds was followed through a commercial processing facility to evaluate the potential movement of herbicide residues from soil, debris, and hulls to almond kernels during processing. Glyphosate was not detected in any almond kernel samples at the end of processing. A glufosinate metabolite, 3-(methylphosphinico)propionic acid (MPP), was detected in kernels at the end of processing at about 0.1 mg kg−1, which is above the EU MRL for total glufosinate. Almonds sampled directly from the tree, without any contact with soil, were found to have elevated MPP residues. This indicates glufosinate or MPP translocation may be a factor in low-level glufosinate residues detected in almonds in some EU exports.

Almonds [Prunus dulcis (Mill.) D.A. Webb] are grown on nearly 650,000 ha in California and generate nearly $4.9 billion in export revenue annually, primarily to the European Union (EU). To facilitate harvest operations, broad-spectrum herbicides such as glyphosate and/or glufosinate are commonly used to control vegetation before harvest. The current minimum preharvest intervals (PHIs) for glyphosate and glufosinate herbicides registered in the United States are 3 and 14 d, respectively. The maximum residue limit (MRL) for glyphosate and glufosinate in almonds in the EU is 0.1 mg kg−1; however, a recent study recommended the glyphosate MRL be reduced to 0.05 mg kg−1. Laboratory and field experiments were conducted to evaluate herbicide transfer from soil to almonds and the effect of longer PHIs on glyphosate and glufosinate residues in harvested almonds. After harvest operations, almonds were dissected into hulls, shells, and kernels for analysis of glyphosate, glufosinate, and their metabolites using liquid chromatography–tandem mass spectroscopy. In the field experiment, glyphosate and glufosinate were detected at 0.121 to 0.291 mg kg−1 in almond hulls and shells. Glyphosate and primary metabolites were below the limit of detection (LOD) in almond kernels at all PHIs. Glufosinate was below the LOD, but the metabolite 3-(methylphosphinico)propionic acid was detected at 0.03 to 0.075 mg kg−1 in kernels from some replicate plots. There were no significant differences in either herbicide or any metabolite among PHI treatments. The lab experiment showed decreasing residue levels from hull to shell to kernel; furthermore, rinsing kernels resulted in 71% and 46% reduction in [14C]glyphosate and [14C]glufosinate, respectively, which suggests much of the herbicide residue may be associated with dust on the kernel surfaces. The results of these experiments indicate very low levels of herbicide transfer from soil to almonds, and increasing the PHI within the tested range did not reduce the already low amounts of herbicide or metabolites in almonds.

OBJECTIVES/GOALS: Use an easily accessible medium to educate life science researchers and academic innovators interested in the commercialization of academic research at the University of Michigan (UM). METHODS/STUDY POPULATION: Life science research investigators and academic innovators interested in research commercialization and technology development from across the state of Michigan were invited to attend the Idea to Impact: The Translation & Commercialization of Academic Research webinar series, presented by Fast Forward Medical Innovation at the University of Michigan. The webinar series outlined the significance and critical milestones of developing novel therapeutics, medical devices, diagnostics, and digital health innovations, as well as essential collaborations with industry partners to translate a research-based idea into a product of impact. RESULTS/ANTICIPATED RESULTS: 113 investigators and innovators from 28 different institutions, organizations, and companies, registered for the webinar series. Results (N=24) of an evaluation immediately following each webinar revealed that 100% of respondents strongly agreed or agreed that the series was effective in helping them to identify and describe commercialization resources, including funding, education, and mentorship, available at the University of Michigan and within the state. Participants stated that they “loved the practical information” “shared” and that the series was a “great overview that inspired a lot more questions.” The Fast Forward Medical Innovation team was then able to consult with participants to connect them with additional resources. DISCUSSION/SIGNIFICANCE: The data suggests that easily accessible and digestible commercialization education can make navigating the academic entrepreneurial ecosystem easier for investigators and innovators. The recorded webinar series, Idea to Impact: The Translation & Commercialization of Academic Research, serves this purpose.

OBJECTIVES/GOALS: The University of Michigan Frankel Cardiovascular Center (FCVC) Innovation Challenge is an annual competition offering funding for innovative ideas to improve cardiovascular care. Due to the COVID-19 pandemic, administrators converted the recruitment process and pitch event to fully virtual. METHODS/STUDY POPULATION: We detail the process of converting the event from a hybrid process (virtual and in-person recruiting and in-person event) to a fully virtual one. Changes to the event included implementing a virtual recruiting process utilizing short video recordings as submission format; a new tool for storing and displaying submissions; fully virtual finalist selection and coaching; and a fully virtual pitch and judging event. The submission process tracked information about submissions that include the type of idea (process or product), role of team lead, and department of team lead. RESULTS/ANTICIPATED RESULTS: The FCVC Innovation Challenge was successfully converted to a fully virtual event. Methods and tools will be shared to allow similar institutions to replicate a successful virtual pitch event. These include methods and tools utilized to allow participants to describe their ideas, strategies to select and coach finalists, and to host a virtual pitch event. Data will be shared on the number of ideas and category (product/process) of projects submitted, and number and category of finalists selected. DISCUSSION/SIGNIFICANCE: This case review can demonstrate how institutions can use a similar virtual idea submission and pitch process to (1) catalyze innovative ideas that can impact patient care by accessing its communitys ideas and (2) fund innovative ideas that do not fit traditional mechanisms.

OBJECTIVES/GOALS: Ask the Experts: A Biomedical Innovation Forum, presented by Fast Forward Medical Innovation (FFMI) at the University of Michigan, provided an opportunity to educate biomedical innovators on life science investment trends and technology assessment criteria. METHODS/STUDY POPULATION: FFMI, in partnership with the U.S. Economic Development Administration, recruited an expert group of panelists to be featured at this virtual event. These life science investment experts provided insight on the strategy, timing, and best method for innovators to engaged investors, the specifics of what investors look for in technologies and project teams, and expectations of investors and project teams after the investment is secured. The panel presentation was followed by a poster presentation highlighting projects from the FFMI Hub at the University of Michigan, allowing innovators to have an open and constructive conversation with experts and attendees. RESULTS/ANTICIPATED RESULTS: There was a total of 73 registrants including academic faculty, biomedical innovators, and life science investment professionals from 21 different academic institutions, private companies, and other organizations. 50 attended the panel presentation and poster session. Results (N=5) of an evaluation of the event revealed that 100% of the respondents strongly agreed or agreed that the event met their expectations, while 80% strongly agreed or agreed that they would recommend the event to a colleague. Feedback from poster presenters was also strong with presenters exclaiming they “enjoyed the panel discussion and getting one-on-one time with the panelists,” as well as “a lot of great advice was given by the experts” and “I really liked the poster presentation part in which I got feedback from the investors.” DISCUSSION/SIGNIFICANCE: The data demonstrates how accelerating technology mining activities, proactively seeking and strengthening external partnerships with investors, and scaling commercialization education programs can have a positive impact on the development and launch of biomedical innovations.

ABSTRACT IMPACT: The successful conversion of an in-person biomedical research commercialization education course to a fully virtual and flipped experience (self-paced) allows greater participation from faculty investigators at CTSA institutions and serves as a model for similar educational programs intended to accelerate the translation of biomedical innovations to products of impact. OBJECTIVES/GOALS: Due to COVID-19, University of Michigan’s Fast Forward Medical Innovation developed new educational resources and leveraged virtual learning tools to convert a successful in-person research commercialization course to a fully virtual, flipped format and evaluated the effectiveness of the converted course compared to the in-person equivalent. METHODS/STUDY POPULATION: Two novel interactive modules (intellectual property and FDA regulation) and five instructional videos (customer discovery, value proposition, opportunity sizing, target product profile, and patent searches) were developed while Constant Contact and Zoom were used for a weekly progression of content delivery and to flip the course: (1) forming/testing value propositions, (2) intellectual property, (3) regulatory, (4) medical reimbursement, (5) business case development. A total of 32 faculty and graduate students completed the virtual, flipped course and submitted a post-course evaluation. Results of the converted course were compared to evaluation results from the in-person course. RESULTS/ANTICIPATED RESULTS: Open rates for the weekly email content were: (1)61%, (2)67%, (3)65%, (4)67%, and (5)59 %. Total views for the modules and videos were: IP-28, regulation-19, customer discovery-62, value proposition-21, opportunity sizing-66, target product profile-11, and patent searches-29. Evaluation results from the virtual course (n=22) were compared to mean results from the 5 previous in-person courses (n=42); 86% of virtual course respondents stated the course met the objectives compared to 85% of in-person respondents; 87% of virtual respondents stated the course met their expectations compared to 100% of in-person; 87% of virtual respondents said they would participate in a follow-up program compared to 94% in-person; 91% of virtual respondents would recommend the course to others compared to 97% of in-person. DISCUSSION/SIGNIFICANCE OF FINDINGS: Email open rates and content views suggest positive flipped participation. Overall, the converted course was comparable to the in-person course at meeting objectives, suggesting the virtual format is effective at delivering the course content and holds the potential for engaging a broader audience.

Traditional training and funding mechanisms in academic health centers often do not support its faculty, staff, and trainees in evaluating and implementing innovative ideas, necessitating supplemental innovation programming. The University of Michigan (U-M) Frankel Cardiovascular Center partnered with U-M Fast Forward Medical Innovation (FMMI), a biomedical innovation and commercialization unit funded in part by the Clinical and Translational Science Award awarded to the Michigan Institute for Clinical & Health Research, to provide training and resources to advance ideas toward impacting patients. The program recruited faculty, trainees, staff, patients, and family members from multidisciplinary backgrounds. Engaging patients and family members expanded the ideas generated and furthered clinical relevance. Over two years, 11 project teams completed an 11-week, 16-session course on innovation and entrepreneurship concepts that incorporated workshops to progress ideas and develop a pitch for development funding. An increase in knowledge was reported in key innovation topics, such as customer discovery, assessing markets, and intellectual property. Participants reported an increase in project preparation, including obtaining stakeholder support, preparation of a development plan, readiness to apply for funding, and filing invention disclosures. This program can serve as a model for implementing training and funding mechanisms to advance innovative ideas.

Dementia-related psychosis (DRP) is common among patients with Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VaD) and is associated with poor outcomes. HARMONY (NCT03325556) was a Phase 3, placebo-controlled, randomized, relapse-prevention study evaluating the efficacy and safety of pimavanserin for treating hallucinations and delusions associated with DRP. Patients with dementia and moderate-severe psychosis received open-label (OL) pimavanserin for 12 weeks. Patients with a sustained response (≥30% reduction in Scale for the Assessment of Positive Symptoms hallucinations+delusions Total Score AND Clinical Global Impression-Improvement score of much/very much improved) at Weeks 8 and 12 were randomized 1:1 to continue pimavanserin or receive placebo for up to 26 weeks in the double-blind (DB) period. The primary endpoint was time from randomization to relapse of DRP. 392 patients enrolled. 217 (61.8%) eligible patients experienced sustained response and were randomized. OL response was similar regardless of dementia subtype (randomization rates: 59.8% AD, 71.2% PDD, 71.4% VaD, 45.5% DLB, 50.0% FTD), baseline disease characteristics, age, dementia severity, or previous drug therapy. The study stopped early for superior efficacy when a prespecified interim analysis revealed >2.8-fold reduction in risk of relapse with pimavanserin (hazard ratio: 0.353; 95% CI: 0.172, 0.727; 1-sided p=0.0023). Adverse event rates were low and balanced (OL: 36.2%; DB: 41.0% pimavanserin, 36.6% placebo). No negative trends for worsening in cognition (as assessed by the Mini-Mental State Examination) or motor function were observed. The HARMONY study demonstrated a robust decrease in hallucinations and delusions and significant maintenance of efficacy with pimavanserin treatment in DRP.

Study Sponsored By: ACADIA Pharmaceuticals Inc.